As has been discussed recently, this compound is easily Wee1 exocytosis again be free or he is responsible for the h Here Cytotoxicity t of liposome-encapsulated MTO fluid membrane than by Kawano et al. MTO fluid membrane charged liposomes with and without ligands were closing Stating their therapeutic effect in a model of brain metastases using the human xenograft tested MT3 breast cancer cells. This model was developed to simulate a metastasis of the primary Ren breast tumors to the brain. Many experiments were conducted to determine the optimal conditions for the growth of intracerebral tumors in terms of the number of cells for transplantation and the growth rate required. An additionally USEFUL transplantation of cells sc parallel in the same mouse in the measurement of the sensitivity of the tumor 3 MT against the MTO allowed. We found that the growth of subcutaneous tumors completely Could be inhibited completely by almost all formulations of MTO. Tend W While targeted liposomes to determine the best formulation, the difference in inhibition was not significant. We have a timetable for the process that began on day 3 after inoculation of tumor cells when the tumors were small, suggesting that the BBB is still intact at this point in time at the beginning. As Ma for the inhibition of growth of the tumor in frozen sections series of mouse brain bcr-abl was determined. The disc with the gr Th Fl che Of the tumor was selected selected And for the analysis.
All formulations caused a significant inhibition of PARP tumor growth with increased Hter inhibition fromfreeMTO intracerebral free ligand liposomes, liposomes carry ligands. The best result was with fluid targeted liposomes significantlymore were effective in inhibiting tumor growth than free MTO and also get the corresponding rigid liposomes. Both liposomal formulations of fluid were significantly better than the free drug, but the difference between these liposomal formulations was not significant. It was also found in the pharmacokinetic study, where we see the drug concentrations in the brain Similar for both types of liposomes and was intended only to improve the drug concentration compared to free MTO in the first minutes after treatment. The therapeutic results show that these Erh Increase the drug concentration in a not very tt apparently sufficient to provide a Erh Increase causing the anti-tumor efficacy. An obvious Docetaxel advantage of liposomalMTOwas also in view of reducing the side effects observed.
Treatment with free MTO with sometimes severe side effects due to the significant loss of body weight K By up to 36% associated diarrhea and dehydration, and manifests the appearance of dandruff. All these side effects was significantly reduced by the same doses of MTO into parameters liposomes, due to their improved biodistribution. Overall, our results show that liposomes liquid membrane significantly improve the therapeutic index of MTO. The advantage of targeted therapy using ligand Angiopep was not as pronounced as in the report of Regina, a big e accumulation of paclitaxel in the brain describes the mouse, after infusion when the drug was conjugated with Angiopep expected. Moreover, the therapeutic effect, which they described their mouse model is not very convincing, because a Erh Increase the life span of only.